Methods for overcoming tazemetostat-resistance in cancer patients
OwnerYaniv Kazansky, Alex Kentsisinventors
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for overcoming tazemetostat resistance in patients diagnosed with or suffering from sarcomas. In some embodiments, the methods of the present technology include administering tazemetostat in combination with an ATR inhibitor, a CDK4/6 inhibitor or an AURK inhibitor.
Claims20
A method for selecting a sarcoma patient for treatment with tazemetostat comprising:
- detecting mRNA or polypeptide expression and/or activity levels of KLF4 in a biological sample obtained from the sarcoma patient that are elevated compared to a control sample obtained from a healthy subject or a predetermined threshold;
- and
- administering to the sarcoma patient an effective amount of tazemetostat.
A method for selecting a sarcoma patient for treatment with tazemetostat and an additional therapeutic agent comprising:
- (A)
- detecting mRNA or polypeptide expression and/or activity levels of one or more of PRICKLE1, PLK1, and CELSR2 in a biological sample obtained from the sarcoma patient that are elevated compared to a control sample obtained from a healthy subject or a predetermined threshold;
- and
- administering to the sarcoma patient an effective amount of tazemetostat and the additional therapeutic agent, wherein the additional therapeutic agent is an ATR inhibitor, an AURK inhibitor or a CDK4/6 inhibitor;
- or
- (B)
- detecting mRNA or polypeptide expression and/or activity levels of KLF4 in a biological sample obtained from the sarcoma patient that are reduced compared to a control sample obtained from a healthy subject or a predetermined threshold;
- and
- administering to the sarcoma patient an effective amount of tazemetostat and the additional therapeutic agent, wherein the additional therapeutic agent is an ATR inhibitor, an AURK inhibitor or a CDK4/6 inhibitor.
(canceled)
A method for treating sarcoma in a patient in need thereof comprising administering to the patient an effective amount of tazemetostat and an effective amount of a CDK4/6 inhibitor, an AURK inhibitor or an ATR inhibitor.
(canceled)
Dependencies are inferred from the claim text.